In this review:
Renal failure among MM patients receiving carfilzomib
Isatuximab ±dexamethasone in relapsed/refractory MM
Different bortezomib schedules with first-line RVd in MM
Idecabtagene vicleucel in relapsed/refractory MM
Real-world bortezomib regimens and Rd for transplant-ineligible MM
Sustained MRD negativity with daratumumab regimens in relapsed/refractory MM
Daratumumab + RVd for newly diagnosed MM
t(4;14) translocations in MM in the novel agent era
Adding salvage autologous SCT and lenalidomide maintenance to Rd for relapsed MM
Please login below to download this issue (PDF)